Access and Evidence
Value for Money
Pharma needs to make the case for the value it brings to the table – and payers need to listen.
More Access and Evidence Articles
Access and Evidence
Breaking Down Barriers for Greater Access to Diabetes Medication
We spoke to Oliver Stahl about access to new diabetes medications in Germany and key European markets.
Access and Evidence
How A Unifying ‘Language Of Medicine’ Has The Potential To Make (And Break) Healthcare.
The unintended impact of healthcare data interoperability.
Access and Evidence
Making the Right Match
Disruptive firm myTomorrows points way towards cheaper drugs and healthier patients.
Access and Evidence
Timely Access: The Waiting Game
Janssen’s Dr Thomas Stark believes the speed of innovation is not matched by that of the medicines approval process.
Access and Evidence
The Future of Real World Evidence in Market Access
How can real world data prove useful at other ends of the value chain?
Access and Evidence
Total Cost of Care Will Define Value Propositions
Understanding where providers and payers are headed is key to pharma sales engagement.
Access and Evidence
Aiming for Better Medical Education in Africa
The challenges of delivering culturally appropriate medical education in African countries and how pharma can help.
Access and Evidence
Drug Pricing and Pharma Reputation: The Experts’ Views
How can pharma increase its reputation in the eyes of the public in 2016 after a difficult year of drug pricing ‘gouging’ claims?
Access and Evidence
Year in Review 2015 - Market Access/Evidence
We bring you the top market access articles of 2015.